To evaluate the impact of psoriasis on pregnancy outcomes.
Introduction
Psoriasis is a chronic autoimmune skin disease that affects approximately 2% of the population (1) . It is commonly characterized by well-demarcated, erythematous plaques with silver scales (2) . The lesions occur mostly on the extensor sur-hypertension, metabolic syndrome, inflammatory bowel disease, serious infections and autoimmune disorders (6) (7) (8) .
Emollients, topical corticosteroids, vitamin D analogs, calcipotriene, calcitriol, tazarotene, calcineurin inhibitors, anthralin, narrowband ultraviolet B (UVB), methotrexate, apremilast and biological agents are the treatment options for psoriasis depending on the severity of the disease (9) . However, no curative treatment has yet been discovered (9) .
The course of psoriasis during pregnancy is usually unpredictable. Psoriasis improves during pregnancy in 40 to 60 percent of women, worsens in 10 to 20 percent, and remains stable in the remainder (1, 10) . Relatively higher rates of improvement may be associated with oestrogen/progesteronemediated immunosuppression during pregnancy (1, 10) . Although increased rates of spontaneous abortion, preterm birth, low birthweight, fetal growth restriction (FGR) and cesarean section (CS) were reported in some studies, the knowledge on the relationship between psoriasis and pregnancy outcomes is limited (1, 2) . Furthermore, choosing the most appropriate treatment protocols during pregnancy is another important issue for physicians (11) . Topical therapy and narrowband UVB are the preferred treatment modalities in this period (11) .
The aim of this study was to evaluate the impact of psoriasis on pregnancy outcomes at a tertiary center.
Material and Method
The data of pregnant women with chronic plaque psoriasis who were followed up at the Division of Perinatology, Hacettepe University Hospital, Ankara between January 1, 2010 and December 31, 2017 were evaluated in this retrospective cohort study. Necessary data were drawn from the "perinatology database".
Pregnant women with singleton pregnancies who had chronic plaque psoriasis were included in the study. Pregnant women with other clinical forms of psoriasis were excluded from the study.
The diagnosis of psoriasis was made according to physical examination, patients' history and skin biopsy in necessary cases by dermatologists (12) . Severity and activation of disease during pregnancy was assessed with physical examination and the Psoriasis Area and Severity Index (PASI, ranging from 0 to 72), which takes into account appearance and extent of the lesions (13) . Topical corticosteroids, emollients, moisturizers and narrowband UVB phototherapy in severe cases were applied to patients with deterioration of the disease.
Spontaneous abortion was defined as a clinically recognized pregnancy loss before the 20th week of gestation (14) . Preterm delivery was defined as delivery that occured before 37 weeks of gestation (15) . Fetal growth restriction (FGR) was defined as <10 th percentile weight for gestational age on a singleton growth curve depending on sonographic biometric measurements (16) . Preeclampsia was defined as the new onset of hypertension and significant end-organ dysfunction with or without proteinuria after 20 weeks of gestation in a previously normotensive woman (17) .
Pregnant women were divided into two groups based on the clinical course of psoriasis during pregnancy: group 1 (improvement/disease-stable), and group 2 (deterioration). Median maternal age, gravida, parity, gestational week at birth, birthweight, 5 th minute APGAR score together with the rates of CS, neonatal intensive care unit (NICU) admission and pregnancy complications (spontaneous abortion, preterm delivery, FGR and preeclampsia) were compared between the groups.
Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS.22, IBM SPSS Statistics for Windows, Version 22.0 Armonk, NY: IBM Corp.). Variables were investigated using visual (histograms, probability plots) and analytical methods (Shapiro-Wilk's test) to determine whether they were normally distributed. Descriptive analyses are presented as medians and interquartile range for non-normally distributed variables. As continuous variables were not normally distributed, the MannWhitney U test was conducted to compare the median values among groups. Categorical variables were defined based on numbers and percentages. Chi-square test was used to compare categorical variables among the groups. A two-tailed P value < 0.05 was regarded as statistically significant.
The study protocol was approved by the Hacettepe University Ethics Committee (GO 18/326).
Results
Improvement of psoriasis was observed in 21 (44.7%) patients. The course of the disease was stable in 8 (17%) patients and deterioration was reported in 18 (38.3%) patients. There were 29 patients in group 1 and 18 patients in group 2. Topical corticosteroids, emollients, and moisturizers were applied to all patients with activation of the disease. Additionally, narrowband UVB phototherapy were applied to 7 patients with severe lesions in group 2.
Mean values for maternal age, gravida and parity were comparable between the groups (p values were 0.32, 0.09 and 0.17, respectively). On the other hand, median values for gestational week at birth (39.2 vs 36.1, p =0.002), birthweight (3200 vs 2310, p =0.002) and 5 th minute APGAR score (9 vs 7, p <0.001) were statistically significantly lower in group 2 compared to group 1. Additionally, CS (33.3% vs 71.4%, p =0.02), NICU admission (11.1% vs 64.3%, p <0.001) and pregnancy complication rates (p =0.003) were statistically significantly higher in group 2. The frequencies of spontaneous abortion, preterm delivery, FGR and preeclampsia were 6.9%, 10.3%, 3.4% and 3.4%, respectively in group 1. However, frequencies of the same parameters in group 2 were 22.2%, 27.8%, 16.7% and 16.7%, respectively (Table 1) .
Discussion
This study demonstrated that deterioration of psoriasis in pregnancy was associated with adverse obstetric outcomes. Gestational week at birth, birthweight and 5 th minute APGAR score were found to be lower in the deterioration group compared to the improvement/disease stable group. Additionally, increased rates of CS, NICU admission and pregnancy complications were observed in the deterioration group.
The relationship between autoimmune diseases and adverse pregnancy outcomes were reported in various studies (18) (19) (20) (21) . Autoimmune antibodies, cell degradation products and inflammatory cytokines were most likely responsible for the injury to vascular structures of the placenta and cellular components of the maternal�fetal interface, resulting in "placental inflammation". Altered biological events and immune system activation might result in impaired implantation and disturbed fetal perfusion (18) (19) (20) (21) . Similar to other autoimmune diseases, psoriasis is characterized by systemic immune dysregulation related to proinflammatory cytokines (1, 22) . Increased activity of Thelper 1 and T-helper 17 cells in the immunopathogenesis of psoriasis were discussed in the current literature (1,3) . T-helper 1 related proinflammatory cytokines interleukin 2 and interferon-γ take part in implantation (1, 23) . Furthermore, interleukin 17 A, which is produced by T-helper 17 cells, plays a protective role from invading pathogens in the decidua (1, 23) . Thus, psoriasis and pregnancy may affect each other by common immunological pathways.
There are a limited number of studies in the literature evaluating the relationship between psoriasis and pregnancy (1, 2, 24) . Usually an improvement in the course of the disease was reported in pregnant women, most probably due to hormonal changes in pregnancy resulting in an immune tolerant state (10, 25) . Improvement of psoriasis was observed in 21 (44.7%) patients in this study, which was consistent with the literature (10, 25) . Another important point is the choice of treatment during pregnancy, since some medications are considered contraindicated (26) . Topical therapies and narrowband UVB phototherapy in severe cases were applied to patients with deterioration of the disease at our institution. No biological agents were used due to limited data on the safety of these medications during pregnancy. However, there are a growing number of studies in the literature demonstrating that biological agents may be used safely during pregnancy (27, 28) .
The relationship between psoriasis and pregnancy outcomes is unclear (1) . According to a recent systematic review of observational studies, increased risk for at least one adverse fetal outcome (spontaneous abortion, CS, low birth weight, macrosomia, large-for-gestational age, or a composite outcome that included prematurity and low birth weight) was reported in four of the nine included studies (1) . However, the study results were inconsistent (1). Systemic immuno-mediated inflammatory processes in psoriasis lead to increased levels of C-reactive protein, fibrinogen and other inflammatory cytokines (2) . Inflammation was reported to be associated with adverse pregnancy outcomes such as preterm birth, low birth weight and preeclampsia (29, 30) . Therefore, a higher rate of pregnancy complications in the disease deterioration group was most probably due to the increased systemic inflammatory response in this group. Additionally, increased rates of CS and NICU admission were related to the higher frequencies of preterm delivery, FGR and preeclampsia in this study. The main strengths of this study were the single center experience and multidisciplinary approach. On the other hand, the limitations of the study were the relatively small number of patients and the retrospective design.
In conclusion, deterioration of psoriasis in pregnancy was associated with adverse obstetric outcomes. Thus, physicians should be cautious in the management of pregnant women with psoriasis, especially in cases with activation of the disease. 
